Zacks Research Downgrades GE HealthCare Technologies (NASDAQ:GEHC) to Strong Sell

GE HealthCare Technologies (NASDAQ:GEHC) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Tuesday,Zacks.com reports.

GEHC has been the subject of several other research reports. Argus lowered their price objective on shares of GE HealthCare Technologies from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Evercore set a $80.00 target price on shares of GE HealthCare Technologies in a report on Thursday, April 30th. Jefferies Financial Group decreased their target price on shares of GE HealthCare Technologies from $105.00 to $90.00 in a research report on Thursday, April 30th. BNP Paribas Exane lowered their price target on shares of GE HealthCare Technologies from $95.00 to $88.00 in a report on Friday, May 1st. Finally, JPMorgan Chase & Co. dropped their price target on GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating for the company in a research report on Thursday, April 30th. Ten analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, GE HealthCare Technologies has a consensus rating of “Hold” and a consensus price target of $76.41.

GE HealthCare Technologies Stock Down 1.0%

Shares of GEHC opened at $61.41 on Tuesday. The stock has a market capitalization of $27.93 billion, a price-to-earnings ratio of 14.69, a price-to-earnings-growth ratio of 1.69 and a beta of 0.72. GE HealthCare Technologies has a 1 year low of $58.75 and a 1 year high of $89.77. The business’s 50 day simple moving average is $63.65 and its 200-day simple moving average is $71.46. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.22 and a quick ratio of 0.95.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its earnings results on Wednesday, April 29th. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.08). GE HealthCare Technologies had a net margin of 9.10% and a return on equity of 20.46%. The business had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same period last year, the business posted $1.01 earnings per share. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. As a group, equities analysts expect that GE HealthCare Technologies will post 4.89 earnings per share for the current fiscal year.

Insider Transactions at GE HealthCare Technologies

In other news, Director Rodney F. Hochman purchased 1,618 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were bought at an average cost of $62.03 per share, for a total transaction of $100,364.54. Following the acquisition, the director owned 1,618 shares of the company’s stock, valued at approximately $100,364.54. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Watkin Phoebe L. Yang acquired 1,000 shares of GE HealthCare Technologies stock in a transaction that occurred on Friday, May 8th. The stock was purchased at an average cost of $63.01 per share, for a total transaction of $63,010.00. Following the completion of the transaction, the director directly owned 13,702 shares in the company, valued at $863,363.02. This trade represents a 7.87% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 21,847 shares of company stock worth $1,361,355. 0.36% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Laurel Wealth Advisors LLC purchased a new stake in shares of GE HealthCare Technologies in the fourth quarter worth approximately $26,000. Optima Capital LLC purchased a new position in GE HealthCare Technologies during the 4th quarter valued at $27,000. Godfrey Financial Associates Inc. purchased a new position in GE HealthCare Technologies during the 4th quarter valued at $27,000. Montag A & Associates Inc. grew its position in GE HealthCare Technologies by 105.4% in the 4th quarter. Montag A & Associates Inc. now owns 341 shares of the company’s stock valued at $28,000 after acquiring an additional 175 shares during the last quarter. Finally, Transamerica Financial Advisors LLC grew its position in GE HealthCare Technologies by 331.6% in the 4th quarter. Transamerica Financial Advisors LLC now owns 341 shares of the company’s stock valued at $28,000 after acquiring an additional 262 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.